Cabaletta Bio (CABA) is back in focus after a cluster of insider share purchases coinciding with fresh FDA clearance to use automated manufacturing platforms for its investigational CAR T cell therapy ...

Cellares recently announced that Cabaletta Bio’s investigational CAR T therapy rese-cel received FDA clearance of an IND ...

SHENZHEN, GUANGDONG, CHINA, January 14, 2026 /EINPresswire.com/ -- As the global automotive interior market shifts ...

Robots are quietly lining up for factory jobs and humans may soon be outnumbered or replaced entirely ...

Digital.ai, the only AI-powered software delivery platform for the enterprise, today announced industry-first support for end-to-end automated testing of Android Auto and Apple CarPlay apps, expanding ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

Key market opportunities in the Automated Parking System sector include growing urbanization and real estate optimization ...

Analysts forecast a fully automated car assembly line by 2030, driven by humanoid robots. This transformation will redefine ...

The former transportation secretary predicted more Americans will become one-car families as the technology is widely adopted ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.